Tixel i® Shows Sustained Relief for Dry Eye Patients
Editorial
1 minute
Tixel i® Shows Sustained Relief for Dry Eye Patients
A recent study published in JOJ Ophthalmology confirms that Novoxel’s FDA-cleared Tixel i® device delivers long-lasting improvements for patients with evaporative dry eye disease caused by Meibomian Gland Dysfunction (MGD). The non-invasive treatment significantly enhanced clinical measures like Tear Break-Up Time and Meibomian Gland Scores, while reducing Ocular Surface Disease Index scores—all without adverse effects. Real-world results at West Plano Dry Eye & Aesthetics echoed the findings, with patients reporting meaningful symptom relief in under two minutes per session. Dr. Lauren Bailey praised Tixel i® as a breakthrough for patients who had exhausted other options.